Combisyn Stungulyf, dreifa 14,0/3,5 % w/v 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

combisyn stungulyf, dreifa 14,0/3,5 % w/v

norbrook laboratories (ireland) limited - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - stungulyf, dreifa - 14,0/3,5 % w/v

Combisyn Tafla 250 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

combisyn tafla 250 mg

norbrook laboratories (ireland) limited - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - tafla - 250 mg

Combisyn Tafla 50 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

combisyn tafla 50 mg

norbrook laboratories (ireland) limited - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - tafla - 50 mg

Noromectin Stungulyf, lausn 1 % w/v 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

noromectin stungulyf, lausn 1 % w/v

norbrook laboratories (ireland) limited - ivermectinum inn - stungulyf, lausn - 1 % w/v

Kaftrio 유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

kaftrio

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cystic fibrosis - Önnur öndunarfæri - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Sugammadex Mylan 유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

sugammadex mylan

mylan ireland limited - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.